H.R. 5526: Biosimilar Red Tape Elimination Act

H.R. 5526 is a federal bill in the 119th Congress. Previously, manufacturers of biosimilar drugs, which are highly similar versions of complex biological medicines, had to submit separate applications and often conduct additional clinical studies to prove their product was interchangeable with a brand-name… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.